Home › Chronic Subdural Hematoma › NCT07324551

Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years old
* Patient or legally authorized representative (LAR) signs an informed consent form
* Confirmed diagnosis of subacute or chronic subdural hematoma, defined as 50% or more chronic blood
* Pre-morbid Modified Rankin Score of ≤ 3

Exclusion Criteria:

* Age \< 18 years old
* Potentially dangerous anatomic variations leading to increased procedural risk or unsafe access for MMA embolization
* Unmanaged, uncontrolled bleeding disorders/blood diathesis
* Presumed septic embolus, or suspicion of microbial superinfection
* Contraindication to angiography
* CT or MRI evidence of intra-cranial tumor or mass lesion

About the study

The purpose of this study is to evaluate the function of matched pair Aristotle 14 Guidewire and Plato Microcatheter in MMA embolization treatment for chronic subdural hematoma compared to surgeon's preference

What is being tested

• Matched pair Aristotle 14 guidewire and Plato 17 microcatheter (device)
• Surgeon combination preference (device)

Sponsor: Ohio State University · Participants: 100 · Started: Nov 3, 2025

Contact the study team

• Edouard Belizaire · Phone: 614.366.6936

Official record on ClinicalTrials.gov — NCT07324551

Locations in the U.S.

Conditions

• Chronic Subdural Hematoma
• Intracranial Hemorrhages

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.